Показано 0 из 0
Дата |
---|
23.02.2022 |
18.02.2022 |
17.02.2022 |
16.02.2022 |
14.02.2022 |
10.02.2022 |
09.02.2022 |
08.02.2022 |
04.02.2022 |
02.02.2022 |
Bid | Ask |
Open |
Min | Max |
Last |
Legal close |
Avg |
Оборот |
Кол-во сделок |
---|---|---|---|---|---|---|---|
1 296.00
|
0
|
1 571.00
|
1 571.00
|
1 599.00
|
1 599.00
|
1 599.00
|
1 587.00
|
11 110.00
|
4.00
|
0
|
1 524.00
|
1 528.00
|
1 524.00
|
1 528.00
|
1 524.00
|
1 526.00
|
1 526.00
|
10 680.00
|
2.00
|
1 198.00
|
0
|
1 457.00
|
1 456.00
|
1 457.00
|
1 456.00
|
1 456.00
|
1 457.00
|
2 913.00
|
2.00
|
0
|
0
|
1 440.00
|
1 440.00
|
1 440.00
|
1 440.00
|
1 440.00
|
1 440.00
|
2 880.00
|
1.00
|
0
|
0
|
1 390.00
|
1 390.00
|
1 432.00
|
1 432.00
|
1 432.00
|
1 410.00
|
22 561.00
|
3.00
|
1 187.00
|
0
|
1 435.00
|
1 435.00
|
1 440.00
|
1 440.00
|
1 440.00
|
1 438.00
|
2 875.00
|
2.00
|
1 296.00
|
0
|
1 425.00
|
1 425.00
|
1 425.00
|
1 425.00
|
1 425.00
|
1 425.00
|
2 850.00
|
1.00
|
0
|
0
|
1 438.00
|
1 438.00
|
1 453.00
|
1 453.00
|
1 453.00
|
1 440.00
|
14 395.00
|
2.00
|
0
|
0
|
1 433.00
|
1 433.00
|
1 433.00
|
1 433.00
|
1 439.00
|
1 439.00
|
35 825.00
|
1.00
|
0
|
0
|
1 412.00
|
1 402.00
|
1 412.00
|
1 402.00
|
1 402.00
|
1 403.00
|
108 024.00
|
3.00
|
Exelixis, Inc. (Exelixis) is a biotechnology company engaged in developing small molecule therapies for the treatment of cancer. The Company is focusing its resources and development efforts on cabozantinib (XL184). It also has a portfolio of other compounds. Cabozantinib is the inhibitor of MET in clinical development and is being evaluated in a development program encompassing multiple cancer indications.